Objectives: Carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa are endemic in many medical centres. Because therapeutic options are limited, understanding the epidemiology and controlling the spread of these pathogens are of paramount importance.
Introduction
Multidrug-resistant Gram-negative pathogens are endemic in most medical centres in New York City. Over the past decade our group has chronicled the epidemiology of multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY, USA. 1 In this report we provide recent trends in resistance concerning these three pathogens and examine hospital-specific factors associated with carbapenem resistance.
Materials and methods

Surveillance study
During a 3 month period in 2009, all single-patient isolates of K. pneumoniae, A. baumannii and P. aeruginosa were collected from the microbiology laboratories in 14 Brooklyn, NY, USA, hospitals. A similar 3 month surveillance study was conducted in 2006 involving the same 14 hospitals. Surveillance isolates were not collected. Susceptibility testing and interpretation of results were performed in the central research laboratory according to CLSI definitions that were in effect at the time of the surveillance. 2 Isolates of K. pneumoniae and A. baumannii with a tigecycline MIC ≤2 mg/L and all isolates with a polymyxin B MIC ≤2 mg/L were considered susceptible. All cephalosporinresistant K. pneumoniae and all isolates of A. baumannii and P. aeruginosa were screened for bla OXA-23-like , bla OXA-24/40-like , bla OXA-58-like , bla OXA-48 , bla VIM , bla IMP and bla KPC genes by PCR using previously defined primers and amplification conditions. 1, 3, 4 Positive controls were included for all carbapenemases except bla OXA-58-like and bla . Amplification of the full-length genes from select strains positive for bla OXA-23-like and bla OXA-24/40-like was done using previously defined primers 5 for OXA-23 and using the following primers for OXA-72: forward (5 ′ -3 ′ ) TCCCCTAA CATGAATTTGTAATGA and reverse CGCATAAGGCGTATTATGTTAATTT. Amplicons of the full-length genes were cloned into the pCR2.1 TOPO vector (Invitrogen, Carlsbad, CA, USA) for sequencing. DNA sequencing was performed with an automated fluorescent dye terminator sequencing system (Applied Biosystems, Foster City, CA, USA). Analysis of carbapenem resistance rates at individual hospitals Analysis of changes in resistance rates was conducted for nine hospitals. These nine hospitals were chosen because (i) there were a sufficient number of isolates for meaningful comparison, and (ii) they provided information on their infection control practices between 2006 and 2009. For each hospital, the percentage of isolates of K. pneumoniae that carried bla KPC and the percentage of carbapenem-resistant A. baumannii and P. aeruginosa were calculated. For the latter two isolates, the rates of resistance to meropenem for A. baumannii and imipenem for P. aeruginosa (the less active of the two carbapenems for each pathogen) were used. For these nine hospitals, the number of carbapenem-resistant isolates and the number of carbapenem-resistant isolates per 10000 patient-days were calculated for 2006 and 2009. Demographic information was obtained for each hospital for 2009. The following information was collected: total staffed beds, total number of discharges, the number of Medicare inpatients on the general medical service, the Medicare case mix index of the general medicine inpatients, and the average length of stay of the medical service patients (which included Medicine, Surgery and their subspecialties). Student's t-test for paired and unpaired data and x 2 analysis were used to compare data. A two-tailed P value ≤0.05 was considered significant.
Results and discussion
K. pneumoniae
A total of 1024 single-patient isolates of K. pneumoniae were gathered in the 14-hospital surveillance study; overall susceptibility results are displayed in Table 1 . Sources of the samples were available for 84% of the isolates: 10% from bloodstream/sterile body fluid, 51% from the urinary tract, 14% from the respiratory tract, 10% from wounds, and 15% from miscellaneous sites. Compared with a surveillance study conducted in 2006 involving the same 14 hospitals, 1 there were significant increases in the susceptibility rates of b-lactam agents. For the three carbapenems included in both the 2006 and current surveillance study, susceptibility rates increased for imipenem (76% versus 79%, P ¼ 0.12), meropenem (76% versus 85%, P,0.001) and ertapenem (61% versus 70%, P,0.001). Of the 1024 isolates, 302 (29%) were found to possess bla KPC , representing a significant (P,0.001) decline from the 38% of isolates identified in 2006. The genes for OXA-23, OXA-24/40, OXA-48, OXA-58, VIM and IMP enzymes were not detected in any isolate. Five of six isolates belonged to two ribotypes known to be endemic to our region, and one was unique. 1 Carbapenem susceptibility rates for KPC-producing K. pneumoniae, using the 2009 CLSI and/or current FDA breakpoints, were 31% for imipenem, 51% for meropenem, 0.6% for doripenem and 2.5% for ertapenem. Using the updated 2010 CLSI breakpoints, 6 the susceptibility rates were 2.5% for imipenem, 2.2% for meropenem, 2.5% for doripenem and 0% for ertapenem. Carbapenem susceptibility rates for K. pneumoniae without bla KPC , using the 2009 CLSI and/or current FDA breakpoints were 100% for imipenem and meropenem, and 98% for doripenem and ertapenem. Using the updated CLSI breakpoints, the susceptibility rates were 98% for imipenem, 96% for meropenem, 99% for doripenem and 96% for ertapenem.
A. baumannii
A total of 378 single-patient isolates of A. baumannii were collected. The sites of origin for the samples were available for 79% of the isolates: 13% from bloodstream/sterile body fluid, 19% from the urinary tract, 50% from the respiratory tract, 16% from wounds, and 2% from miscellaneous sites. Results of the MIC testing are shown in Table 1 . There was a marked Table 1 . Susceptibility of K. pneumoniae, A. baumannii and P. aeruginosa collected during the 14 hospital surveillance study 
P. aeruginosa
A total of 616 single-patient isolates of P. aeruginosa were collected ( Table 1 ). The sources of the samples were available for 82% of the isolates: 6% from bloodstream/sterile body fluid, 32% from the urinary tract, 36% from the respiratory tract, 16% from wounds, and 10% from miscellaneous sites. Compared with the surveillance study conducted in 2006, 1 there was a significant decrease in susceptibility for imipenem (69% to 61%, P ¼ 0.005), while that of meropenem remained unchanged (77% versus 74%, P ¼not significant). The genes for KPC, OXA-23, OXA-24/40, OXA-58, VIM and IMP enzymes were not detected in any isolate.
Analysis of carbapenem resistance rates at individual hospitals
Changes in the rates of carbapenem resistance for the three pathogens between 2006 and 2009 were analysed for nine hospitals (Table 2 ). For the 2009 isolates, these hospitals accounted for 80%, 82% and 82% of all of the K. pneumoniae, A. baumannii and P. aeruginosa, respectively, that were submitted during the surveillance study. Six hospitals had significant declines in the rate of bla KPC -possessing K. pneumoniae (from 9.06+4.65 to 3.73+2.08 cases/10 000 patient-days, P ¼0.04). Although the total number of K. pneumoniae isolates was similar in 2006 and 2009 for these six hospitals (563 and 529, respectively), there was a significant decrease in the proportion of isolates with bla KPC [from 204 of 563 (36%) to 97 of 529 (18%), P ¼ 0.0001]. For these six hospitals, the rates of meropenemresistant A. baumannii (from 6.83+3.97 to 5.17+1.69 cases/ 10 000 patient-days, P ¼ 0.37) and of imipenem-resistant P. aeruginosa (from 4.04+2.36 to 4.24+2.23 cases/10 000 patient-days, P ¼ 0.78) were unchanged from 2006 to 2009.
In contrast, three hospitals experienced non-significant increases in the rate of K. pneumoniae with bla KPC (from 8.46+4.80 to 15.32+8.96 cases/10 000 patient-days, P ¼ 0.14), A. baumannii (from 11.73+5.64 to 16.79+6.81 cases/10 000 patient-days, P ¼ 0.30) and P. aeruginosa (from 5.57+4.13 to 13.33+10.31 cases/10 000 patient-days, P ¼ 0.16) from 2006 to 2009. 
Carbapenem resistance in New York City
Further analysis was performed to elucidate why six hospitals had a significant decline in resistant Klebsiella (and modest decreases in Acinetobacter and Pseudomonas) while three hospitals did not. Compared with the other three hospitals, the six hospitals with a significant improvement with resistant K. pneumoniae in 2009 had shorter lengths of stay for medical/ surgical patients (6.56+0.79 versus 9.10+1.39 days, P ¼ 0.009). There was no difference between the two groups regarding the number of hospital beds, annual discharges, Medicare inpatients or the Medicare case mix index. Five hospitals with declines in resistant K. pneumoniae had policies, since 2006, for contact precautions for patients infected/colonized with Gram-negative pathogens resistant to extended-spectrum cephalosporins. One hospital provided contact precautions for patients with multidrug-resistant pathogens (defined as resistance to three or more classes of agents). Since 2006, none of the hospitals had initiated programmes that cohorted patients (although one had an existing policy that had been in place prior to 2006), none assigned dedicated staff for these patients, and two had developed educational programmes regarding multidrug-resistant Gram-negative pathogens. Three of the six had an increase in the number of infection control staff since 2006, and only one performed rectal surveillance cultures for carbapenem-resistant Gram-negative pathogens. This hospital had the greatest reduction in the resistant K. pneumoniae from 2006 to 2009; the success of this programme has been reported in detail elsewhere. 7 The three hospitals that did not have improvement against resistant K. pneumoniae also had policies for contact precautions for patients with pathogens resistant to extended-spectrum cephalosporins; two had implemented a policy for immediate initiation of contact precautions for patients readmitted with a known history of infection or colonization with multidrug-resistant pathogens. None of the three hospitals initiated policies to cohort patients between 2006 and 2009 (although two had pre-existing policies already in place), none assigned dedicated staff to care for these patients, and two of the hospitals had implemented educational programmes. One hospital had an increase in infection control personnel since 2006, while one had a decrease. Rectal surveillance cultures were not performed in any of the three hospitals.
Our surveillance studies indicate diverging directions in our effectiveness to control resistance in Gram-negative pathogens. On the one hand, modest but significant improvements have been made in our control of KPC-possessing K. pneumoniae. The overall percentage of K. pneumoniae possessing bla KPC has decreased from 2006 to 2009, with marked declines noted in several individual hospitals. As all surveyed hospitals had infection control protocols targeting these pathogens in place, and only some had significant reductions in the rate of KPC-possessing K. pneumoniae, it remains difficult to discern which infection control measures are essential. It is noteworthy that the single hospital described in this report that had the greatest decrease in the percentage of KPC-possessing K. pneumoniae employed rectal surveillance cultures. Rectal surveillance cultures were also used in the other successful interventions to control the spread of KPC-positive K. pneumoniae.
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Also, hospitals with a decline in KPC-possessing K. pneumoniae had shorter average lengths of stay among medical/surgical patients. This may represent a modifiable factor to augment infection control efforts.
On the other hand, our attempts to control the spread of two resistant non-fermenters, A. baumannii and P. aeruginosa, have clearly failed. The introduction of OXA-type carbapenemases in our region has added to the resistance burden among A. baumannii. There are likely several factors that account for the measurable success seen in controlling the spread of KPC-possessing K. pneumoniae but not carbapenem-resistant A. baumannii and P. aeruginosa. First, the hospital epidemiology, and their mode of transmission, may be different. KPC-possessing K. pneumoniae colonize the gastrointestinal tract, and identifying carriers may be an important infection control modality. 7 -9 When studied, environmental contamination of KPCpositive bacteria does not seem to be common. 10 In contrast, A. baumannii and P. aeruginosa are often recovered from respiratory samples, environmental contamination may be commonplace and the potential for air-borne spread has been documented. 11 Second, carbapenem resistance in K. pneumoniae almost always requires the acquisition of a potent carbapenemase on a transmissible element. Interrupting the spread of the genetic element with the carbapenemase gene will effectively halt the spread of carbapenem resistance in K. pneumoniae. However, both A. baumannii (with increased expression of bla OXA-51-like carbapenemase 12 ) and P. aeruginosa (with reduced oprD expression) possess intrinsic mechanisms that can lead to carbapenem resistance. Therefore, transmission of cephalosporinsusceptible isolates (against which infection control efforts are typically not directed) may allow the spread of pathogens with the ability to become carbapenem-resistant if placed under appropriate pressure. It is possible that interrupting the spread of carbapenem-resistant A. baumannii and P. aeruginosa may require intensified environmental cleaning, respiratory isolation and infection control efforts against all isolates, regardless of susceptibility.
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